About: Aviva Lev-Ari, PhD, RN
- Website
- http://pharmaceuticalintelligence.wordpress.com
- Details
- Founder & Director of Leaders in Pharmaceutical Business Intelligence (LPBI) Venture Value Creator @LPBI: VENTURE #1: e-Publishing: Medicine, HealthCare, Life Sciences, BioMed, Pharmaceutical Open Access Online Scientific Journal http://pharmaceuticalintelligence.com VENTURE #2: BioMedical e-Books e-Series: Cardiovascular, Genomics, Cancer, BioMed, Patient Centered Medicine http://pharmaceuticalintelligence.com/biomed-e-books/ VENTURE #3: International Scientific Delegations http://pharmaceuticalintelligence.com/scientific-delegation VENTURE #4: Funding, Deals & Partnerships http://pharmaceuticalintelligence.com/joint-ventures/ Corporate Clients for our Services Funding Cardiovascular Medical Devices Development Funding Biologics Development Funding Diagnostics Funding Partnerships in IP Development M&A and Exit Targeting Penetration in New Markets for High Technology Products Management of Engineering Design of Prototypes Outsourcing VENTURE #5: IP Invented HERE! VENTURE # 6: PRESS Coverage of Conferences http://pharmaceuticalintelligence.com/press-coverage/ - University of California, Berkeley, PhD '83 - Stanford University - GSB Exchange Program, 1980/81 - Northeastern University, Biological Sciences & Nursing '07 Worked at Director level with Start-ups and Fortune 100 companies making presentations at the CEO Board Room level. Start ups: TimeØ Group, Concept Five Technologies, Inc., MDSS, Inc.; Top Tier Management Consulting: SRI International, Monitor Group; OEM: Amdahl Corporation; Top 6th System Integrator: Perot System Corporation; FFRDC: MITRE Corporation. In the Publishing industry: McGraw-Hill/CTB. Researcher on Cardiovascular Pharmaco-therapy at Bouve College of Health Sciences, Northeastern University.
Posts by Aviva Lev-Ari, PhD, RN:
-
January 10, 2026 Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter
-
January 10, 2026 Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com
-
January 8, 2026 The youngest leader in AI in Health: Tanishq Mathew Abraham, Ph.D. (@iScienceLuvr)
-
January 6, 2026 2026 Grok Multimodal Causal Reasoning on Proprietary Cariovascular Corpus: From 2021 Wolfram NLP Baseline to Thousands of Novel Relationships – A Second Head-to-Head Validation of LPBI’s Domain-Aware Training Advantage
-
January 6, 2026 Workflow for Dynamic Linkage and Transition between two Authoring Systems: LPBI Group’s WordPress.com Multi-Authors Authoring System and Microsoft PowerPoint product for Slide show presentation – Part 10.1 in Composition of Methods
-
December 15, 2025 2025 Grok 4.1 Causal Reasoning & Multimodal on Identical Proprietary Oncology Corpus: From 673 to 5,312 Novel Biomedical Relationships: A Direct Head-to-Head Comparison with 2021 Static NLP – NEW Foundation Multimodal Model in Healthcare: LPBI Group’s Domain-aware Corpus Transforms Grok into the “Health Go-to Oracle”
-
December 8, 2025 Marquee Followers 80% Healthcare Persons and Institutions for @AVIVA1950 and @Pharma_BI
-
December 8, 2025 Exploratory Protocol for Comparison of NLP to LLM on Same Oncology Slice
-
December 8, 2025 Valuation Models per Ten Digital IP Asset Classes in LPBI Group’s Portfolio of IP
-
December 5, 2025 Protected: How Gold 🥇and Silver Medals for Grok Will Be Achieved in Domain-Aware “AI in Health”: Pharmaceutical/BioPharma, Medical/Diagnosis and Therapeutics, Life Sciences/Genomics and BioMed/Biotech/Medtech
Follow Blog via Email
Join 2,041 other subscribers-
Recent Posts
- FDA Moves Forward With Its Guidance Framework for Rare Disease Trials: 2026 August 3, 2026
- Artificial Intelligence TRANSFORMS Medicine, Biotech and Healthcare, How? August 3, 2026
- In Memoriam: Nobel Laureate J. Michael Bishop for discovery of Retroviral Oncogenes July 31, 2026
- Companies Actively Engaging Artificial Intellegence for Drug Design: 2026 July 31, 2026
- AI-Native Drug Discovery Landscape 2026 – How LPBI Group Differentiates in the New Era of Foundation Models July 19, 2026
- In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
- Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
- 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
- Protected: KOL on Competitive Dynamics: LPBI Group’s Founder’s Radar Screens on AI-in-Health, Life Sciences & BioPharma June 15, 2026
- Tumor Infiltrating Lymphocytes (TIL) as a first of kind FDA approved immunotherapy for cancer June 12, 2026
Archives
Categories
Meta